• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by LeMaitre Vascular Inc.

    8/9/24 10:11:12 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care
    Get the next $LMAT alert in real time by email
    S-8 1 lmat20240808_s8.htm FORM S-8 lmat20240808_s8.htm

    As filed with the Securities and Exchange Commission on August 8, 2024

    Registration No. 333-

     


     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     


     

    FORM S-8 

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     


     

    LEMAITRE VASCULAR, INC.

    (Exact name of registrant as specified in its charter)

     


       

    Delaware

    04-2825458

    (State or other jurisdiction of

    incorporation or organization)

    (I.R.S. Employer

    Identification No.)

     

    63 Second Avenue

    Burlington, Massachusetts 01803

    (781) 221-2266

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     


     

    LEMAITRE VASCULAR, INC. FOURTH AMENDED AND

    RESTATED 2006 STOCK OPTION AND INCENTIVE PLAN

    (Full title of plan)

     


     

    George W. LeMaitre

    Chairman and Chief Executive Officer

    LeMaitre Vascular, Inc.

    63 Second Avenue

    Burlington, Massachusetts 01803

    (781) 221-2266

    (Name, address and telephone number, including area code, of agent for service)

     


     

    copy to:

     

    John R. Pitfield

    Choate, Hall & Stewart LLP

    Two International Place

    Boston, Massachusetts 02110

    (617) 248-5000 

     


     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

           

    Large accelerated filer

    ☒

    Accelerated filer

    ☐

           

    Non-accelerated filer

    ☐

    Smaller reporting company

    ☐

           
       

    Emerging growth company

    ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     


     

     

     

     


    EXPLANATORY NOTE

     

    This registration statement on Form S-8 is filed by LeMaitre Vascular, Inc., a Delaware corporation (the “Company”), to register an additional 1,000,000 shares of its common stock, $0.01 par value per share (“Common Stock”), for issuance pursuant to the LeMaitre Vascular, Inc. Fourth Amended and Restated 2006 Stock Option and Incentive Plan (the “Plan”). The Plan was described in the Company’s definitive Proxy Statement for its 2024 Annual Meeting of Stockholders held on June 3, 2024 and was approved by the Company’s stockholders at that meeting.

     

    The 1,000,000 shares being registered hereby are in addition to the shares of Common Stock registered by the Company’s prior registration statements on Form S-8 filed on June 30, 2015 (File No. 333-205360), May 11, 2011 (File No. 333-174129), August 14, 2009 (File No. 333-161361) and October 24, 2006 (File No. 333-138181) (collectively, the “Prior Registration Statements”). After giving effect to the additional shares registered under this registration statement, the aggregate number of shares registered for issuance under the Plan will be 6,500,000, plus the number of shares representing expired, cancelled or terminated stock options or awards under the Company’s prior 1997 Stock Option Plan, 1998 Stock Option Plan, 2000 Stock Option Plan and 2004 Stock Option Plan.

     

    This registration statement relates to securities of the same class as that to which the Prior Registration Statements relate and is submitted in accordance with General Instruction E to Form S-8 as promulgated by the Securities and Exchange Commission (the “Commission”) regarding Registration of Additional Securities. Pursuant to such instruction, the contents of the Prior Registration Statements are incorporated herein by reference and made part of this registration statement to the extent not modified or superseded hereby or by a subsequently filed document that is incorporated by reference herein or therein. In accordance with the instructional note to Part I of Form S-8, the information specified by Part I of Form S-8 has been omitted from this registration statement. The document(s) containing the information specified by Part I of Form S-8 will be sent or given to participants as specified by Securities Act Rule 428(b)(1).

     


    PART II

     

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3.

    Incorporation of Documents by Reference

     

    The following documents of the Company filed with the Commission are hereby incorporated by reference in this registration statement:

     

    (a) The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed on February 29, 2024 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”);

     

    (b) The Company’s Quarterly Report on Form 10-Q filed with the Commission on May 10, 2024;

     

    (c) The Company’s Current Reports on Form 8-K filed with the Commission on June 3, 2024;

     

    (d) All other reports filed by the Company pursuant to Section 13(a) or 15(d) of the Exchange Act since December 31, 2023; and

     

    (e) The description of the Company’s Common Stock contained in Exhibit 4.2 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 filed on March 12, 2020 under the Securities Exchange Act.

     

     

     

     

    In addition, all documents filed by the Company after the initial filing date of this registration statement pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, and prior to the filing of a post-effective amendment which indicates that all shares registered hereunder have been sold or which deregisters all shares then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to be a part hereof from the date of filing of such documents. Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this registration statement to the extent that a statement contained herein or in any subsequently filed document which also is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this registration statement.

     

    Item 4.

    Description of Securities

     

    Not applicable.

     

    Item 5.

    Interests of Named Experts and Counsel

     

    Not applicable.

     

    Item 6.

    Indemnification of Officers and Directors

     

    The Delaware General Corporation Law and the Registrant’s charter and bylaws provide for indemnification of the Registrant’s directors and officers for liabilities and expenses that they may incur in such capacities. In general, the Registrant will indemnify its directors and officers with respect to actions taken by them in good faith in a manner reasonably believed to be in, or not opposed to, the Registrant’s best interests and, with respect to any criminal action or proceeding, actions that the indemnitee had no reasonable cause to believe were unlawful. Reference is made to the Registrant’s bylaws and charter filed as Exhibits 3.1, 3.2 and 3.3 to this Registration Statement, respectively.

     

    The Registrant has entered into agreements with certain of its officers and directors that also provide for such indemnification and expenses and liability reimbursement. These agreements require the Registrant to indemnify such persons against liabilities that may arise by reason of their status or service as officers and directors and to advance their expenses incurred as a result of any proceeding against them as to which they could be indemnified. Reference is made to the Registrant’s form of Indemnification Agreement filed as Exhibit 10.17 to the Registrant’s Registration Statement on Form S-1 filed on May 26, 2006 (File No. 333-133532). In addition, the Registrant has an existing directors and officers liability insurance policy to insure such persons against certain liabilities.

     

    Item 7.

    Exemption from Registration Claimed

     

    Not applicable.

     

     

     

     

    Item 8.

    Exhibits

     

     

     

     

     

    Incorporation by Reference

     

     

    Exhibit
    No.
      Description  

    Form

     

    Location

     

    Filing

    Date

      Filed
    Herewith

    3.1

     

    Second Amended and Restated Certificate of Incorporation of LeMaitre Vascular, Inc.

     

    10-K

     

    3.2

     

    3/29/10

       

    3.2

     

    Amendment to Second Amended and Restated Certificate of Incorporation of LeMaitre Vascular, Inc.

     

    8-K

     

    3.3

     

    6/15/12

       

    3.3

     

    Amended and Restated Bylaws of LeMaitre Vascular, Inc.

     

    S-1/A

     

    3.1

     

    5/26/06

       

    4.1

     

    Specimen Certificate Representing the Common Stock

     

    S-1/A

     

    4.1

     

    6/22/06

       

    4.2

     

    Description of Common Stock

     

    10-K

     

    4.2

     

    3/12/20

       

    5.1

     

    Opinion of Choate, Hall & Stewart LLP

                 

    x

    23.1

     

    Consent of Grant Thornton LLP

                 

    x

    24.1

     

    Power of Attorney (included in the signature page hereto)

                 

    x

    99.1

     

    LeMaitre Vascular, Inc. Fourth Amended and Restated 2006 Stock Option and Incentive Plan

     

    8-K

     

    10.1

     

    6/3/24

       

    107.1

     

    Filing Fee Table

                 

    x

     

    Item 9.

    Undertakings

     

    (a) The Company hereby undertakes:

     

    (1) To file, during any period in which offers or sales of the securities offered hereby are being made, a post-effective amendment to this registration statement:

     

    (i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

     

    (ii) To reflect in the prospectus any facts or events arising after the effective date of this registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20 percent change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement;

     

    (iii) To include any material information with respect to the plan of distribution not previously disclosed in this registration statement or any material change to such information in this registration statement;

     

    provided, however, that paragraphs (a)(1)(i) and (a)(1)(ii) above do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Company pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this registration statement.

     

    (2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

     

    (b) The Company hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Company’s annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.

     

    (h) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Company pursuant to the foregoing provisions, or otherwise, the Company has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Company of expenses incurred or paid by a director, officer or controlling person of the Company in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Company will, unless in the opinion of counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

     

     

     

     


    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing a Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Burlington, Massachusetts on August 8, 2024.

     

     

    LEMAITRE VASCULAR, INC.

       

    By:

    /s/ George W. LeMaitre

     

    George W. LeMaitre

     

    Chief Executive Officer

     

     

     

     

    POWER OF ATTORNEY

     

    KNOW ALL PERSONS BY THESE PRESENTS, that each individual whose signature appears below constitutes and appoints George W. LeMaitre and Joseph P. Pellegrino, Jr., jointly and severally, his or her true and lawful attorneys-in-fact and agents with full powers of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue thereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed below on the dates indicated by the following persons in the capacities indicated.

     

    Name

    Title

    Date

         

    /s/ George W. LeMaitre

    Chief Executive Officer and Chairman of the

    August 8, 2024

    George W. LeMaitre Board of Directors
    (Principal Executive Officer)
     
         

    /s/ Joseph P. Pellegrino, Jr.

    Chief Financial Officer and Director

    August 8, 2024

    Joseph P. Pellegrino, Jr. (Principal Financial Officer and Principal Accounting Officer)  
         

    /s/ Lawrence J. Jasinski

    Director

    August 8, 2024

    Lawrence J. Jasinski    
         

    /s/ John J. O’Connor

    Director

    August 8, 2024

    John J. O’Connor    
         

    /s/ David B. Roberts

    Director

    August 8, 2024

    David B. Roberts    
         

    /s/ Bridget A. Ross

    Director

    August 8, 2024

    Bridget A. Ross    
         

    /s/ John A. Roush

    Director

    August 8, 2024

    John A. Roush    
         
    /s/ Martha Shadan Director August 8, 2024
    Martha Shadan    

     

     
    Get the next $LMAT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LMAT

    DatePrice TargetRatingAnalyst
    8/6/2025$95.00Mkt Perform → Outperform
    Barrington Research
    2/28/2025Outperform → Perform
    Oppenheimer
    2/28/2025Outperform → Mkt Perform
    Barrington Research
    2/13/2025$95.00Equal Weight
    Wells Fargo
    10/15/2024$96.00Neutral
    Cantor Fitzgerald
    8/2/2024$85.00 → $105.00Buy
    Lake Street
    5/31/2024$100.00Buy
    ROTH MKM
    4/26/2024$59.00 → $75.00Hold → Buy
    Stifel
    More analyst ratings

    $LMAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and Director Roberts David B exercised 2,679 shares at a strike of $37.32, increasing direct ownership by 12% to 24,930 units (SEC Form 4)

    4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)

    2/6/26 4:48:58 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    Senior V. P., Operations Kamke Trent G exercised 2,344 shares at a strike of $42.67, increasing direct ownership by 53% to 6,761 units (SEC Form 4)

    4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)

    1/12/26 5:16:50 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    Chairman and CEO Lemaitre George W exercised 26,277 shares at a strike of $47.18, covered exercise/tax liability with 1,978 shares, gifted 12,100 shares and was granted 12,100 shares, increasing direct ownership by 0.73% to 1,682,304 units (SEC Form 4)

    4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)

    12/15/25 6:14:32 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    $LMAT
    SEC Filings

    View All

    SEC Form 10-Q filed by LeMaitre Vascular Inc.

    10-Q - LEMAITRE VASCULAR INC (0001158895) (Filer)

    11/7/25 6:59:20 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form 8-K/A filed by LeMaitre Vascular Inc.

    8-K/A - LEMAITRE VASCULAR INC (0001158895) (Filer)

    11/6/25 9:00:30 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    LeMaitre Vascular Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - LEMAITRE VASCULAR INC (0001158895) (Filer)

    11/6/25 4:03:44 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    $LMAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lemaitre Vascular upgraded by Barrington Research with a new price target

    Barrington Research upgraded Lemaitre Vascular from Mkt Perform to Outperform and set a new price target of $95.00

    8/6/25 7:37:02 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    Lemaitre Vascular downgraded by Oppenheimer

    Oppenheimer downgraded Lemaitre Vascular from Outperform to Perform

    2/28/25 8:28:09 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    Lemaitre Vascular downgraded by Barrington Research

    Barrington Research downgraded Lemaitre Vascular from Outperform to Mkt Perform

    2/28/25 7:39:54 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    $LMAT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LeMaitre to Participate in Upcoming Investor Conferences

    BURLINGTON, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that management will participate in three upcoming investor conferences. Jefferies London Healthcare Conference 2025 Tuesday, November 18, 2025Waldorf Hilton, LondonDorian LeBlanc, CFO, will present at 8:00 AM GMT Wolfe Research 7th Annual Healthcare Conference Wednesday, November 19, 2025Wolfe NYC Offices, New York, NYDavid Roberts, President, will present at 10:40 AM ET Piper Sandler 37th Annual Healthcare Conference Thursday, December 4, 2025Lotte Palace, New York, NYDorian LeBlanc, CFO, will present at 3:20 PM ET About LeMaitre LeMaitre is a provider of devices, implants,

    11/12/25 4:13:25 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    LeMaitre Q3 2025 Financial Results

    BURLINGTON, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of vascular devices, implants, and services, today reported Q3 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance. Q3 2025 results include a non-recurring benefit from the Employee Retention Tax Credit. Non-GAAP adjusted figures exclude this benefit. A reconciliation of GAAP to non-GAAP results is included. Q3 2025: Sales $61.0mm, +11% (+12% organic)Gross margin 75.3% (+750 bps), adjusted 70.8% (+300 bps)Op. income $20.3mm (+54%), adjusted $16.9mm (+29%)Op. margin 33%, adjusted 28%Diluted EPS $0.75 (+54%), adjusted $0.62 (+27%)Cash up $23.6mm sequentiall

    11/6/25 4:05:00 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    LeMaitre Will Announce Third Quarter 2025 Earnings Results on November 6, 2025

    BURLINGTON, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its third quarter 2025 financial results on Thursday, November 6, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay at ir.lemaitre.com. About LeMaitre LeMaitre is a provider of devices, implants, and services for the treatment

    10/9/25 5:53:13 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    $LMAT
    Leadership Updates

    Live Leadership Updates

    View All

    Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

    MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. "On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company" commented John Seaberg, Chairman o

    6/9/25 10:52:06 PM ET
    $AVR
    $LMAT
    Industrial Specialties
    Health Care
    Medical/Dental Instruments

    Precision Optics Appoints Joseph P. Pellegrino, Jr. to Board of Directors

    GARDNER, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Joseph P. "JJ" Pellegrino, Jr. to its Board of Directors. Mr. Pellegrino, who will also serve as Chairman of the Board's Audit Committee, brings decades of operational and financial experience as well as an extensive knowledge of the medical device industry to the board. Mr. Pellegrino most recently served as Chief Financial Officer of LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of devices, implants and services for the treatm

    3/20/25 9:00:00 AM ET
    $LMAT
    $POCI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    Former Johnson & Johnson Executive Joins Advisory Board at Maitri Health Technologies

    Bridget Ross brings extensive experience in MedTech development and services;Joins advisory board of healthcare, logistics, capital markets and innovation leaders VANCOUVER, BC, March 23, 2021 /PRNewswire/ - Maitri Health Technologies Corp. ("Maitri") (CSE: MTEC) (FRA: D84), a global platform for healthcare supply security, today announced the appointment of Bridget Ross to its Advisory Board. Ms. Ross is currently CEO of ChroniSense Medical, Ltd., an Israel-based MedTech company and maker of wearable, medical-grade disease management devices. Ms. Ross serves as a Board Director for LeMaitre Vascular Inc. (NASDAQ: LMAT) and as a mentor for early stage MedTech companies through MassMEDIC and

    3/23/21 8:00:00 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    $LMAT
    Financials

    Live finance-specific insights

    View All

    LeMaitre Q3 2025 Financial Results

    BURLINGTON, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of vascular devices, implants, and services, today reported Q3 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance. Q3 2025 results include a non-recurring benefit from the Employee Retention Tax Credit. Non-GAAP adjusted figures exclude this benefit. A reconciliation of GAAP to non-GAAP results is included. Q3 2025: Sales $61.0mm, +11% (+12% organic)Gross margin 75.3% (+750 bps), adjusted 70.8% (+300 bps)Op. income $20.3mm (+54%), adjusted $16.9mm (+29%)Op. margin 33%, adjusted 28%Diluted EPS $0.75 (+54%), adjusted $0.62 (+27%)Cash up $23.6mm sequentiall

    11/6/25 4:05:00 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    LeMaitre Will Announce Third Quarter 2025 Earnings Results on November 6, 2025

    BURLINGTON, Mass., Oct. 09, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its third quarter 2025 financial results on Thursday, November 6, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay at ir.lemaitre.com. About LeMaitre LeMaitre is a provider of devices, implants, and services for the treatment

    10/9/25 5:53:13 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    LeMaitre Q2 2025 Financial Results

    BURLINGTON, Mass., Aug. 05, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of vascular devices, implants, and services, today reported Q2 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance. Q2 2025: Sales $64.2mm, +15% (+15% organic)Gross margin 70.0%, +110 bpsOp. income $16.1mm, +12%Op. margin 25%Earnings per diluted share $0.60, +16%Cash up $16.9mm sequentially to $319.5mm Catheters (+27%) and grafts (+19%) drove Q2 sales growth. EMEA sales increased 23%, Americas 12%, and APAC 12%. Price accounted for 8% of sales growth and units 7%. Gross margin of 70.0% (vs. 68.9% in Q2 2024) increased due to higher average selling prices

    8/5/25 4:05:16 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    $LMAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by LeMaitre Vascular Inc.

    SC 13G - LEMAITRE VASCULAR INC (0001158895) (Subject)

    10/22/24 3:49:21 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by LeMaitre Vascular Inc. (Amendment)

    SC 13G/A - LEMAITRE VASCULAR INC (0001158895) (Subject)

    2/13/24 5:08:02 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by LeMaitre Vascular Inc. (Amendment)

    SC 13G/A - LEMAITRE VASCULAR INC (0001158895) (Subject)

    2/12/24 3:02:21 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care